{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:44:37Z","timestamp":1786553077793,"version":"build-2736575974"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":505,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to report safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) over 36\u2009weeks in the ongoing FOREST-HCM trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients were started on aficamten 5\u2009mg daily, with doses adjusted in 5-mg increments (5\u201320\u2009mg) at \u22652-week intervals according to site-read left ventricular ejection fraction (LVEF). Aficamten dose was increased if LVEF \u226555%, maintained if LVEF 50\u201354%, decreased if LVEF 40\u2013&amp;lt;50%, and temporarily interrupted if LVEF &amp;lt;40%. Safety and efficacy were assessed over 36\u2009weeks. Overall, 34 patients were enrolled (mean age 57.2\u2009\u00b1\u200915.3\u2009years, 62% female, 41% in New York Heart Association [NYHA] class III). Over 36\u2009weeks, 82.3% achieved 15\u201320\u2009mg daily dose and there was a modest reduction in LVEF by \u22124.3% \u00b1\u20095.2 from 70% \u00b1\u20096.1 (p\u2009&amp;lt;\u20090.0001). At Week 36, NYHA class improved by \u22651 class in 27 (79.4%) patients. Mean Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 13.8\u2009\u00b1\u200912.5 points relative to baseline. Median (interquartile range) levels of N-terminal pro-B-type natriuretic peptide were significantly improved from baseline (\u2212665.5\u2009pg\/ml [\u22121244.0, \u2212232.0]; p\u2009&amp;lt;\u20090.0001), while high-sensitivity cardiac troponin I was unchanged (\u22122.7 ng\/L [\u221211.3, 1.6]; p\u2009=\u20090.25). There were no drug discontinuations due to adverse events. LVEF &amp;lt;50% occurred in 2 (5.9%) patients, one following pulmonary vein isolation and one associated with atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over 36\u2009weeks, aficamten appeared safe and effective in the studied patients with nHCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3372","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:24:15Z","timestamp":1721294655000},"page":"1993-1998","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and Efficacy of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: A 36-Week Analysis from FOREST-HCM"],"prefix":"10.1093","volume":"26","author":[{"given":"Ahmad","family":"Masri","sequence":"first","affiliation":[{"name":"Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de A Coru\u00f1a , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[{"name":"Barts Heart Centre and University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Oreziak","sequence":"additional","affiliation":[{"name":"National Institute of Cardiology , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albree","family":"Tower-Rader","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I.","family":"Malik","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Melloni","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wei","sequence":"additional","affiliation":[{"name":"Cytokinetics Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"University of Michigan Medical Center , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FOREST-HCM Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"2026010913051203200_ejhf3372-bib-0001","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051203200_ejhf3372-bib-0002","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"2026010913051203200_ejhf3372-bib-0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051203200_ejhf3372-bib-0004","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J Card Fail"},{"key":"2026010913051203200_ejhf3372-bib-0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026010913051203200_ejhf3372-bib-0006","article-title":"Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: Results from the REDWOOD-HCM trial, cohort 4","author":"Masri","journal-title":"J Card Fail"},{"key":"2026010913051203200_ejhf3372-bib-0007","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051203200_ejhf3372-bib-0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026010913051203200_ejhf3372-bib-0009","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051203200_ejhf3372-bib-0010","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051203200_ejhf3372-bib-0011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1253\/circj.CJ-10-0782","article-title":"Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy","volume":"75","author":"Kubo","year":"2011","journal-title":"Circ J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1993\/65511429\/eurjhf_26_9_1993.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1993\/65511429\/eurjhf_26_9_1993.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:06Z","timestamp":1767981966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/9\/1993\/8328664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":11,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,18]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3372","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}